These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 1854252

  • 21. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B.
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2.
    Schoof DD, Terashima Y, Batter S, Douville L, Richie JP, Eberlein TJ.
    Urology; 1993 Jun; 41(6):534-9. PubMed ID: 8516989
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
    Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell D.
    J Immunother (1991); 1992 Apr; 11(3):184-90. PubMed ID: 1515423
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
    Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM.
    J Natl Cancer Inst; 1988 Mar 02; 80(1):60-3. PubMed ID: 3257526
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A, Savona S, Gafney E, Penichet KO, Lin BY, Levitt D, Ahmed T, Arlin ZA, Baskind P, Needleman D.
    J Biol Response Mod; 1989 Oct 02; 8(5):468-78. PubMed ID: 2795092
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lymphokine-activated killer traffic assay and our preliminary clinical results of regional arterial infusion of lymphokine-activated killer cells for renal cell carcinoma.
    Hayakawa M, Koyama Y, Williams RD, Osawa A.
    Urol Int; 1991 Oct 02; 47 Suppl 1():127-31. PubMed ID: 1949369
    [Abstract] [Full Text] [Related]

  • 33. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW, Fuchs HA.
    J Rheumatol; 1994 Apr 02; 21(4):752-3. PubMed ID: 8035405
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ.
    J Clin Oncol; 1995 Aug 02; 13(8):1939-49. PubMed ID: 7636534
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec 02; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.